Skip to main content

68th Annual Scientific Meeting (AHS 2026) Main banner

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Presentation Icons

Red Recording

Sig Meeting

Browse by Poster Title

Browse by Poster Title

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#

R
T 62
Real-world effectiveness and safety of CGRP monoclonal antibodies in elderly migraine patients: a Korean multicenter study

Favorite
T 15
Real-World Impact of Eptinezumab Treatment on Migraine-Related Cognitive Symptoms in Participants in Whom ≥1 Prior CGRP-Targeted Therapy had Failed: 12-Month Results of a Prospective Study

Favorite
T 83
Real-World Longitudinal Outcomes of Acute Rimegepant in a Tertiary Migraine Population

Favorite
E 55
Real-World Migraine Treatment Patterns in the Era of CGRP-Targeted Therapies: Low Preventive Uptake and Dynamic Regimen Shifts: A Retrospective Claims Analysis

Favorite
E 7
Real-world Racial and Ethnic Differences in Migraine Treatment Access: Results from the HeAD-US Study

Favorite
T 76
Real-World Use of the Remote Electrical Neuromodulation (REN) Wearable for Migraine Management in Hawaii Demonstrates Positive Patient Outcomes: A Pilot Study

Favorite
TR 6
Reduced Cardiovagal activity is Strongly Associated with Treatment Resistance in Patients with Migraine

Favorite
T 77
Regional Patterns of Online Interest in Erenumab: A Comparative Study of the United States and Europe

Favorite
E 27
Relationship Between Migraine Related Stigma and Quality of Life in a Black/African American Sample

Favorite
E 22
Retrospective Review of Suicide Screening Results in VA Neurology Telehealth Program

Favorite
CR 7
Rimegepant as an Acute Therapy for Cluster Headache: A Case Report

Favorite
CR 16
Rimegepant for Medication Overuse Headache in a 93-Year-Old: A Novel Role for Calcitonin Gene-Related Peptide (CGRP) Antagonism

Favorite
T 22
Rimegepant for the Preventive Treatment of Migraine: A Phase 3, Randomized, Double-blind, Placebo-controlled Study in Adults from China

Favorite